Overview

A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)

Status:
Recruiting

Trial end date:
2023-07-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of mirabegron in children (5 to < 12 years of age) with OAB. This study will also evaluate the safety and tolerability of mirabegron in pediatric participants with OAB and evaluate the pharmacokinetics after multiple dose administration of mirabegron in pediatric participants with OAB.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Treatments:

Mirabegron